K Kengkla1, N Charoensuk2, M Chaichana2, S Puangjan2, T Rattanapornsompong2, J Choorassamee1, P Wilairat1, S Saokaew3. 1. School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand; Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand. 2. School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand. 3. School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand; Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand. Electronic address: saokaew@gmail.com.
Abstract
BACKGROUND: Extended spectrum β-lactamase-producing Escherichia coli (ESBL-EC) has important implications for infection control and empiric antibiotic prescribing. This study aims to develop a risk scoring system for predicting ESBL-EC infection based on local epidemiology. METHODS: The study retrospectively collected eligible patients with a positive culture for E. coli during 2011 to 2014. The risk scoring system was developed using variables independently associated with ESBL-EC infection through logistic regression-based prediction. Area under the receiver-operator characteristic curve (AuROC) was determined to confirm the prediction power of the model. FINDINGS: Predictors for ESBL-EC infection were male gender [odds ratio (OR): 1.53], age ≥55 years (OR: 1.50), healthcare-associated infection (OR: 3.21), hospital-acquired infection (OR: 2.28), sepsis (OR: 1.79), prolonged hospitalization (OR: 1.88), history of ESBL infection within one year (OR: 7.88), prior use of broad-spectrum cephalosporins within three months (OR: 12.92), and prior use of other antibiotics within three months (OR: 2.14). Points scored ranged from 0 to 47, and were divided into three groups based on diagnostic performance parameters: low risk (score: 0-8; 44.57%), moderate risk (score: 9-11; 21.85%) and high risk (score: ≥12; 33.58%). The model displayed moderate power of prediction (AuROC: 0.773; 95% confidence interval: 0.742-0.805) and good calibration (Hosmer-Lemeshow χ(2) = 13.29; P = 0.065). CONCLUSION: This tool may optimize the prescribing of empirical antibiotic therapy, minimize time to identify patients, and prevent spreading of ESBL-EC. Prior to adoption into routine clinical practice, further validation study of the tool is needed.
BACKGROUND: Extended spectrum β-lactamase-producing Escherichia coli (ESBL-EC) has important implications for infection control and empiric antibiotic prescribing. This study aims to develop a risk scoring system for predicting ESBL-EC infection based on local epidemiology. METHODS: The study retrospectively collected eligible patients with a positive culture for E. coli during 2011 to 2014. The risk scoring system was developed using variables independently associated with ESBL-EC infection through logistic regression-based prediction. Area under the receiver-operator characteristic curve (AuROC) was determined to confirm the prediction power of the model. FINDINGS: Predictors for ESBL-EC infection were male gender [odds ratio (OR): 1.53], age ≥55 years (OR: 1.50), healthcare-associated infection (OR: 3.21), hospital-acquired infection (OR: 2.28), sepsis (OR: 1.79), prolonged hospitalization (OR: 1.88), history of ESBL infection within one year (OR: 7.88), prior use of broad-spectrum cephalosporins within three months (OR: 12.92), and prior use of other antibiotics within three months (OR: 2.14). Points scored ranged from 0 to 47, and were divided into three groups based on diagnostic performance parameters: low risk (score: 0-8; 44.57%), moderate risk (score: 9-11; 21.85%) and high risk (score: ≥12; 33.58%). The model displayed moderate power of prediction (AuROC: 0.773; 95% confidence interval: 0.742-0.805) and good calibration (Hosmer-Lemeshow χ(2) = 13.29; P = 0.065). CONCLUSION: This tool may optimize the prescribing of empirical antibiotic therapy, minimize time to identify patients, and prevent spreading of ESBL-EC. Prior to adoption into routine clinical practice, further validation study of the tool is needed.
Authors: Anna C Sick-Samuels; Katherine E Goodman; Glenn Rapsinski; Elizabeth Colantouni; Aaron M Milstone; Andrew J Nowalk; Pranita D Tamma Journal: J Pediatric Infect Dis Soc Date: 2020-04-30 Impact factor: 3.164
Authors: Yanhong Jessika Hu; Anju Ogyu; Benjamin J Cowling; Keiji Fukuda; Herbert H Pang Journal: Bull World Health Organ Date: 2019-05-14 Impact factor: 9.408
Authors: Mathupanee Oonsivilai; Yin Mo; Nantasit Luangasanatip; Yoel Lubell; Thyl Miliya; Pisey Tan; Lorn Loeuk; Paul Turner; Ben S Cooper Journal: Wellcome Open Res Date: 2018-10-10
Authors: Merel M C Lambregts; Bart J C Hendriks; Leo G Visser; Sandra T Bernards; Mark G J de Boer Journal: Antimicrob Resist Infect Control Date: 2019-01-25 Impact factor: 4.887
Authors: J W Timotëus Deelen; Wouter C Rottier; José A Giron Ortega; Jesús Rodriguez-Baño; Stephan Harbarth; Evelina Tacconelli; Gunnar Jacobsson; Jean-Ralph Zahar; Cornelis H van Werkhoven; Marc J M Bonten Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079